[1]
|
Azevedo, O., Gago, M.F., Miltenberger-Miltenyi, G., Sousa, N. and Cunha, D. (2020) Fabry Disease Therapy: State- of-the-Art and Current Challenges. International Journal of Molecular Sciences, 22, Article 206.
https://doi.org/10.3390/ijms22010206
|
[2]
|
Michaud, M., Mauhin, W., Belmatoug, N., et al. (2021) [Fabry Disease: A Review]. La Revue de Médecine Interne, 42, 110-119. (In French) https://doi.org/10.1016/j.revmed.2020.08.019
|
[3]
|
Tuttolomondo, A., Simonetta, I., Riolo, R., et al. (2021) Patho-genesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies. International Journal Of Molecular Sciences, 22, Article 10088. https://doi.org/10.3390/ijms221810088
|
[4]
|
Shen, J.S., Balaji, U., Shigeyasu, K., et al. (2022) Dysregulated DNA Methylation in the Pathogenesis of Fabry Disease. Molecular Genetics and Metabolism Reports, 33, Article ID: 100919.
https://doi.org/10.1016/j.ymgmr.2022.100919
|
[5]
|
Branton, M.H., Schiffmann, R., Sabnis, S.G., et al. (2002) Natural History of Fabry Renal Disease: Influence of α-Galactosidase A Activity and Genetic Mutations on Clinical Course. Medicine, 81, 122-138.
https://doi.org/10.1097/00005792-200203000-00003
|
[6]
|
Kok, K., Zwiers, K.C., Boot, R.G., Overkleeft, H.S., Aerts, J.M.F.G. and Artola, M. (2021) Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions. Biomolecules, 11, Article 271.
https://doi.org/10.3390/biom11020271
|
[7]
|
Echevarria, L., Benistan, K., Toussaint, A., et al. (2016) X-Chromosome Inactivation in Female Patients with Fabry Disease. Clinical Genetics, 89, 44-54. https://doi.org/10.1111/cge.12613
|
[8]
|
Maue, M., Glynn, E., Svarstad, E., et al. (2014) Mosaicism of Podocyte Involvement Is related to Podocyte Injury in Females with Fabry Disease. PLOS ONE, 9, e112188. https://doi.org/10.1371/journal.pone.0112188
|
[9]
|
Macdermot, K.D., Holmes, A. and Miners, A.H. (2001) An-derson-Fabry Disease: Clinical Manifestations and Impact of Disease in a Cohort of 60 Obligate Carrier Females. Journal of Medical Genetics, 38, 769-775.
https://doi.org/10.1136/jmg.38.11.769
|
[10]
|
Azevedo, O., Gal, A., Faria, R., et al. (2020) Founder Effect of Fabry Disease Due to p.F113L Mutation: Clinical Profile of a Late-Onset Phenotype. Molecular Genetics and Metabolism, 129, 150-160.
https://doi.org/10.1016/j.ymgme.2019.07.012
|
[11]
|
Chien, Y.H., Lee, N.C., Chiang, S.-C., Desnick, R.J. and Hwu, W.-L. (2012) Fabry Disease: Incidence of the Common Later-Onset α-Galactosidase A IVS4+919G→A Mutation in Taiwanese Newborns—Superiority of DNA-Based to Enzyme-Based Newborn Screening for Common Mutations. Mo-lecular Medicine, 18, 780-784.
https://doi.org/10.2119/molmed.2012.00002
|
[12]
|
Harzer, K., Beck-Wodl, S. and Haack, T.B. (2022) Angiokerato-ma Corporis Diffusum with Severe Acroparesthesia, an Endothelial Abnormality and Inconspicuous Genetic Findings. Journal of Cutaneous Pathology, 49, 293-298.
https://doi.org/10.1111/cup.14154
|
[13]
|
Nagai-Sangawa, M., Fukunaga, A., Takeuchi, C., et al. (2022) Beneficial Screening of Fabry Disease in Patients with Hypohidrosis. The Journal of Dermatology, 49, 308-312. https://doi.org/10.1111/1346-8138.16237
|
[14]
|
Lidove, O., Ramaswami, U., Jaussaud, R., et al. (2006) Hyperhi-drosis: A New and Often Early Symptom in Fabry Disease. International Experience and Data from the Fabry Outcome Survey. International Journal of Clinical Practice, 60, 1053-1059. https://doi.org/10.1111/j.1742-1241.2006.01061.x
|
[15]
|
Ortiz, A., Oliveira, J.P., Waldek, S., et al. (2008) Nephrop-athy in Males and Females with Fabry Disease: Cross-Sec- tional Description of Patients before Treatment with Enzyme Replacement Therapy. Nephrology Dialysis Transplantation, 23, 1600-1607. https://doi.org/10.1093/ndt/gfm848
|
[16]
|
Warnock, D.G., Thomas, C.P., Vujkovac, B., et al. (2015) Antiproteinuric Therapy and Fabry Nephropathy: Factors Associated with Preserved Kidney Function during Agalsidase-Beta Therapy. Journal of Medical Genetics, 52, 860- 866. https://doi.org/10.1136/jmedgenet-2015-103471
|
[17]
|
Abensur, H. and Reis, M.A. (2016) Renal Involvement in Fabry Disease. Brazilian Journal of Nephrology, 38, 245-254.
https://doi.org/10.5935/0101-2800.20160034
|
[18]
|
Graziani, F., Lillo, R., Biagini, E., et al. (2022) Myocardial In-farction with Non-Obstructive Coronary Arteries in Hypertrophic Cardiomyopathy vs Fabry Disease. International Journal of Cardiology, 369, 29-32.
https://doi.org/10.1016/j.ijcard.2022.07.046
|
[19]
|
Sado, D.M., White, S.K., Piechnik, S.K., et al. (2013) Identifica-tion and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 mapping. Circulation: Cardiovascular Imaging, 6, 392-398. https://doi.org/10.1161/CIRCIMAGING.112.000070
|
[20]
|
Aquaro, G.D., De Gori, C., Faggioni, L., et al. (2022) Cardiac Magnetic Resonance in Fabry Disease: Morphological, Functional and Tissue Features. Diagnostics, 12, Article 2652. https://doi.org/10.3390/diagnostics12112652
|
[21]
|
Sims, K., Politei, J., Banikazemi, M., et al. (2009) Stroke in Fabry Disease Frequently Occurs before Diagnosis and in the Absence of other Clinical Events: Natural History Data from the Fabry Registry. Stroke, 40, 788-794.
https://doi.org/10.1161/STROKEAHA.108.526293
|
[22]
|
Liu, D., Hu, K., Schmidt, M., et al. (2018) Value of the CHA2DS2-VASc Score and Fabry-Specific Score for Predicting New-Onset or Recurrent Stroke/TIA in Fabry Disease Patients without Atrial Fibrillation. Clinical Research in Cardiology, 107, 1111-1121. https://doi.org/10.1007/s00392-018-1285-4
|
[23]
|
Nilsson, M., Kolagari, H.T., Epstein, D., et al. (2022) Visual Outcome, Ocular Findings and Visual Quality of Life in Patients with Fabry Disease. Ophthalmic Genetics, 43, 841-849. https://doi.org/10.1080/13816810.2022.2132515
|
[24]
|
Van Der Tol, L., Sminia, M.L., Hollak, C.E. and Bieg-straaten, M. (2016) Cornea Verticillata Supports a Diagnosis of Fabry Disease in Non-Classical Phenotypes: Results from the Dutch Cohort and a Systematic Review. British Journal of Ophthalmology, 100, 3-8. https://doi.org/10.1136/bjophthalmol-2014-306433
|
[25]
|
Bitirgen, G., Turkmen, K., Zengin, N. and Malik, R.A. (2021) Altered Pupillary Light Responses Are Associated with the Severity of Autonomic Symptoms in Patients with Fabry Disease. Scientific Reports, 11, Article No. 8146.
https://doi.org/10.1038/s41598-021-87589-x
|
[26]
|
Yazdanfard, P.D.W., Effraimidis, G., Madsen, C.V., et al. (2022) Hearing Loss in Fabry Disease: A 16 Years Follow-Up Study of the Danish Nationwide Cohort. Molecular Genetics and Metabolism Reports, 31, Article ID: 100841.
https://doi.org/10.1016/j.ymgmr.2022.100841
|
[27]
|
Mersebach, H., Johansson, J.O., Rasmussen, A.K., et al. (2007) Osteopenia: A Common Aspect of Fabry Disease. Predictors of Bone Mineral Density. Genetics in Medicine, 9, 812-818.
https://doi.org/10.1097/GIM.0b013e31815cb197
|
[28]
|
Politei, J., Frabasil, J., Durand, C., et al. (2021) Incidental Finding of Cornea Verticillata or Lamellar Inclusions in Kidney Biopsy: Measurement of lyso-Gb3 in Plasma Defines between Fabry Disease and Drug-Induced Phospholipidosis. Biochimica et Biophysica Acta (BBA): Molecular Basis of Disease, 1867, Article ID: 165985.
https://doi.org/10.1016/j.bbadis.2020.165985
|
[29]
|
Smid, B.E., Van Der Tol, L., Biegstraaten, M., et al. (2015) Plasma Globotriaosylsphingosine in Relation to Phenotypes of Fabry disease. Journal of Medical Genetics, 52, 262-268. https://doi.org/10.1136/jmedgenet-2014-102872
|
[30]
|
Rusu, E.E., Zilisteanu, D.S., Ciobotaru, L.M., et al. (2022) The Impact of Kidney Biopsy for Fabry Nephropathy Evaluation on Patients’ Management and Long-Term Outcomes: Experience of a Single Center. Biomedicines, 10, Article 1520. https://doi.org/10.3390/biomedicines10071520
|
[31]
|
Torra, R. (2008) Renal Manifestations in Fabry Disease and Therapeutic Options. Kidney International, 74, S29-3S2.
https://doi.org/10.1038/ki.2008.522
|
[32]
|
Kim, I.Y., Lee, H.J. and Cheon, C.K. (2021) Fabry Nephropathy before and after Enzyme Replacement Therapy: Important Role of Renal Biopsy in Patients with Fabry Disease. Kidney Re-search and Clinical Practice, 40, 611-619.
https://doi.org/10.23876/j.krcp.21.056
|
[33]
|
Van Der Tol, L., Smid, B.E., Poorthuis, B.J., et al. (2014) A Systematic Review on Screening for Fabry Disease: Prevalence of Individuals with Genetic Variants of Unknown Significance. Journal of Medical Genetics, 51, 1-9.
https://doi.org/10.1136/jmedgenet-2013-101857
|
[34]
|
Sodre, L.S.S., Huaira, R., Colugnati, F.A.B., et al. (2021) Screening of Family Members of Chronic Kidney Disease Patients with Fabry Disease Mutations: A very Important and Underrated Task. Brazilian Journal of Nephrology, 43, 28-33.
|
[35]
|
Kubota, T., Tsukimura, T., Shiga, T., et al. (2022) Monitoring of Anti-Drug Antibodies and Disease-Specific Biomarkers in Three Patients from a Japanese Fabry Family Treated with Enzyme Replacement Therapy. CEN Case Reports, 12, 171-175. https://doi.org/10.1007/s13730-022-00738-7
|
[36]
|
Anisha, G.S. (2023) Biopharmaceutical Applications of α-Galactosidases. Biotechnology and Applied Biochemistry, 70, 257-267. https://doi.org/10.1002/bab.2349
|
[37]
|
Li, Q., Wang, J., Tian, M., et al. (2023) Clinical Features and Enzyme Replacement Therapy in 10 Children with Fabry dis-ease. Frontiers in Pediatrics, 11, Article 1084336. https://doi.org/10.3389/fped.2023.1084336
|
[38]
|
Stucky, C.L. and Mikesell, A.R. (2021) Cutaneous Pain in Disorders Affecting Peripheral Nerves. Neuroscience Letters, 765, Article ID: 136233. https://doi.org/10.1016/j.neulet.2021.136233
|
[39]
|
Sun, L., Zi, X., Wang, Z., et al. (2022) IgA Nephropathy with Mimicking Fabry Disease: A Case Report and Literature Review. Medicine, 101, e31060. https://doi.org/10.1097/MD.0000000000031060
|
[40]
|
Saeed, S. and Imazio, M. (2022) Fabry Disease: Definition, Incidence, Clinical Presentations and Treatment—Focus on cardiac Involvement. Pakistan Journal of Medical Sciences, 38, 2337-2344. https://doi.org/10.12669/pjms.38.8.7063
|
[41]
|
Gościniak, P., Baron, T., Milczarek S, et al. (2022) Updates for the Diagnosis and Management of Cardiac Amyloidosis. Advances in Clinical and Experimental Medicine, 31, 175-185. https://doi.org/10.17219/acem/142252
|
[42]
|
Chimenz, R., Chirico, V., Cuppari, C., et al. (2022) Fabry Disease and Kidney Involvement: Starting from Childhood to Understand the Future. Pediatric Nephrology, 37, 95-103. https://doi.org/10.1007/s00467-021-05076-x
|
[43]
|
Muntean, C., Starcea, I.M., Stoica, C. and Banescu, C. (2022) Clinical Characteristics, Renal Involvement, and Therapeutic Options of Pediatric Patients with Fabry Disease. Frontiers in Pediatrics, 10, Article 908657.
https://doi.org/10.3389/fped.2022.908657
|
[44]
|
Oder, D., Muntze, J. and Nordbeck, P. (2021) Contemporary Therapeutics and New Drug Developments for Treatment of Fabry Disease: A Narrative Review. Cardiovascular Diag-nosis and Therapy, 11, 683-695.
https://doi.org/10.21037/cdt-20-743
|